See more : Wallbox N.V. (WBX) Income Statement Analysis – Financial Results
Complete financial analysis of Alnylam Pharmaceuticals, Inc. (ALNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alnylam Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kolon Global Corporation (003075.KS) Income Statement Analysis – Financial Results
- American Pacific Rim Commerce Group (APRM) Income Statement Analysis – Financial Results
- Gladstone Investment Corporation (GAINM) Income Statement Analysis – Financial Results
- Shanxi Coal International Energy Group Co.,Ltd (600546.SS) Income Statement Analysis – Financial Results
- Paras Defence and Space Technologies Limited (PARAS.BO) Income Statement Analysis – Financial Results
Alnylam Pharmaceuticals, Inc. (ALNY)
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.83B | 1.04B | 844.29M | 492.85M | 219.75M | 74.91M | 89.91M | 47.16M | 41.10M | 50.56M | 47.17M | 66.73M | 82.76M | 100.04M | 100.53M | 96.16M | 50.90M | 26.93M | 5.72M | 4.28M | 176.00K | 0.00 |
| Cost of Revenue | 310.41M | 168.82M | 140.14M | 78.05M | 25.06M | 1.80M | 13.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.52B | 868.60M | 704.14M | 414.80M | 194.69M | 73.11M | 76.55M | 47.16M | 41.10M | 50.56M | 47.17M | 66.73M | 82.76M | 100.04M | 100.53M | 96.16M | 50.90M | 26.93M | 5.72M | 4.28M | 176.00K | 0.00 |
| Gross Profit Ratio | 83.02% | 83.73% | 83.40% | 84.16% | 88.60% | 97.59% | 85.13% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.00B | 883.02M | 792.16M | 654.82M | 655.11M | 505.42M | 390.64M | 382.39M | 276.50M | 190.25M | 112.96M | 86.57M | 99.30M | 106.38M | 108.73M | 96.88M | 120.69M | 49.80M | 35.32M | 24.60M | 13.10M | 3.34M |
| General & Administrative | 795.65M | 770.66M | 620.64M | 588.42M | 479.01M | 382.36M | 199.37M | 89.35M | 60.61M | 44.53M | 27.15M | 44.61M | 38.28M | 37.73M | 39.91M | 27.12M | 23.39M | 16.63M | 13.87M | 11.94M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 795.65M | 770.66M | 620.64M | 588.42M | 479.01M | 382.36M | 199.37M | 89.35M | 60.61M | 44.53M | 27.15M | 44.61M | 38.28M | 37.73M | 39.91M | 27.12M | 23.39M | 16.63M | 13.87M | 11.94M | 7.53M | 880.00K |
| Other Expenses | 0.00 | -109.37M | -2.05M | 45.53M | 20.73M | 4.17M | -3.02M | 6.17M | 76.00K | 1.82M | -47.00K | 331.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.80B | 1.65B | 1.41B | 1.24B | 1.13B | 887.78M | 590.00M | 471.75M | 337.11M | 234.78M | 140.11M | 131.18M | 137.58M | 144.11M | 148.64M | 124.00M | 144.07M | 66.43M | 49.19M | 36.54M | 20.62M | 4.22M |
| Cost & Expenses | 2.11B | 1.82B | 1.55B | 1.32B | 1.16B | 889.58M | 590.00M | 471.75M | 337.11M | 234.78M | 140.11M | 131.18M | 137.58M | 144.11M | 148.64M | 124.00M | 144.07M | 66.43M | 49.19M | 36.54M | 20.62M | 4.22M |
| Interest Income | 95.56M | 24.81M | 1.58M | 11.81M | 33.45M | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977.00K | 1.21M | 2.31M | 5.39M | 14.41M | 15.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 121.22M | 155.97M | 143.02M | 84.50M | 0.00 | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977.00K | 1.21M | 2.31M | 5.39M | 872.00K | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 54.05M | 44.47M | 47.57M | 34.77M | 17.18M | 6.44M | 13.37M | 15.13M | 19.05M | 11.93M | 10.23M | 9.04M | 5.13M | 4.94M | 5.99M | 5.73M | 4.08M | 3.82M | 3.12M | 2.44M | 838.00K | 36.00K |
| EBITDA | -258.24M | -926.56M | -661.56M | -736.33M | -868.08M | -754.24M | -488.19M | -409.46M | -276.96M | -172.29M | -82.71M | -51.71M | -49.69M | -38.06M | -41.02M | -18.93M | -75.06M | -35.69M | -38.83M | -29.55M | -19.61M | -4.19M |
| EBITDA Ratio | -14.12% | -86.22% | -83.99% | -156.46% | -427.50% | -1,115.02% | -556.20% | -900.33% | -720.27% | 72.29% | -197.05% | -23.29% | -65.60% | -50.45% | -47.38% | -23.62% | -174.50% | -131.57% | -705.58% | -691.61% | -8,507.39% | 0.00% |
| Operating Income | -282.18M | -785.07M | -708.65M | -828.44M | -939.43M | -814.67M | -500.09M | -424.59M | -296.01M | -404.98M | -92.94M | -129.46M | -54.82M | -44.07M | -48.11M | -27.84M | -93.18M | -39.50M | -43.47M | -32.26M | -25.06M | -4.22M |
| Operating Income Ratio | -15.43% | -75.68% | -83.93% | -168.09% | -427.50% | -1,087.56% | -556.20% | -900.33% | -720.27% | -800.97% | -197.05% | -194.01% | -66.24% | -44.05% | -47.86% | -28.95% | -183.07% | -146.68% | -760.53% | -754.18% | -14,236.93% | 0.00% |
| Total Other Income/Expenses | -151.34M | -341.92M | -143.49M | -27.16M | 54.18M | 54.00M | 9.21M | 14.48M | 5.94M | 4.38M | 1.02M | 12.87M | -2.83M | 1.07M | 1.10M | 2.31M | 12.96M | 4.89M | 558.00K | -390.00K | -4.64M | 0.00 |
| Income Before Tax | -433.52M | -1.13B | -852.14M | -855.60M | -885.25M | -760.67M | -490.87M | -410.11M | -290.07M | -400.60M | -91.92M | -116.59M | -57.65M | -43.00M | -47.01M | -25.53M | -80.22M | -34.61M | -42.91M | -35.37M | -29.69M | 0.00 |
| Income Before Tax Ratio | -23.71% | -108.63% | -100.93% | -173.60% | -402.85% | -1,015.48% | -545.95% | -869.63% | -705.83% | -792.32% | -194.88% | -174.73% | -69.66% | -42.98% | -46.76% | -26.55% | -157.61% | -128.51% | -750.77% | -826.72% | -16,871.59% | 0.00% |
| Income Tax Expense | 6.73M | 4.16M | 680.00K | 2.68M | 863.00K | 823.00K | -25.60M | -23.44M | -24.91M | -40.21M | -2.70M | -10.57M | -5.80M | 514.00K | 582.00K | 719.00K | 5.25M | -4.89M | -558.00K | 390.00K | 4.59M | -86.00K |
| Net Income | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.50M | -490.87M | -410.11M | -290.07M | -360.40M | -89.23M | -106.01M | -57.65M | -43.52M | -47.59M | -26.25M | -85.47M | -34.61M | -42.91M | -32.65M | -25.03M | -4.14M |
| Net Income Ratio | -24.08% | -109.04% | -101.01% | -174.15% | -403.24% | -1,016.58% | -545.95% | -869.63% | -705.83% | -712.79% | -189.17% | -158.88% | -69.66% | -43.50% | -47.34% | -27.30% | -167.92% | -128.51% | -750.77% | -763.30% | -14,223.30% | 0.00% |
| EPS | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| EPS Diluted | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| Weighted Avg Shares Out | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.67K | 331.34K |
| Weighted Avg Shares Out (Dil) | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.67K | 331.34K |
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
The 3 Best Gene Editing Stocks to Buy in August 2024
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2024 Earnings Call Transcript
Alnylam (ALNY) Reports Q2 Earnings: What Key Metrics Have to Say
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Alnylam Stock Is a Blockbuster Biopharma In the Making
35% Surge Just the Beginning? Alnylam's Stock Poised for Massive Gains on Heart Drug Success.
Source: https://incomestatements.info
Category: Stock Reports